Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $46...
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...
TG Therapeutics (NASDAQ:TGTX) raises FY2025 sales outlook from $585.000 million to $600.000 million vs $588.045 million estimate.
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $0.22...
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...
